NO923252L - Fosfoinositolglykan-peptid med insulinlignende virkning - Google Patents

Fosfoinositolglykan-peptid med insulinlignende virkning

Info

Publication number
NO923252L
NO923252L NO92923252A NO923252A NO923252L NO 923252 L NO923252 L NO 923252L NO 92923252 A NO92923252 A NO 92923252A NO 923252 A NO923252 A NO 923252A NO 923252 L NO923252 L NO 923252L
Authority
NO
Norway
Prior art keywords
insulin effect
phosphoinositol glycan
glycan peptide
insulin
peptide
Prior art date
Application number
NO92923252A
Other languages
English (en)
Other versions
NO303452B1 (no
NO923252D0 (no
Inventor
Guenter Mueller
Dominique Tripier
Stefan Muellner
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO923252D0 publication Critical patent/NO923252D0/no
Publication of NO923252L publication Critical patent/NO923252L/no
Publication of NO303452B1 publication Critical patent/NO303452B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO923252A 1991-08-20 1992-08-19 Fosfoinositolglykan-peptid med insulinlignende virkning, fremgangsmÕte for fremstilling, legemiddel og anvendelse av forbindelsen for fremstilling av et legemiddel NO303452B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4127495 1991-08-20

Publications (3)

Publication Number Publication Date
NO923252D0 NO923252D0 (no) 1992-08-19
NO923252L true NO923252L (no) 1993-02-22
NO303452B1 NO303452B1 (no) 1998-07-13

Family

ID=6438668

Family Applications (1)

Application Number Title Priority Date Filing Date
NO923252A NO303452B1 (no) 1991-08-20 1992-08-19 Fosfoinositolglykan-peptid med insulinlignende virkning, fremgangsmÕte for fremstilling, legemiddel og anvendelse av forbindelsen for fremstilling av et legemiddel

Country Status (22)

Country Link
US (1) US5624903A (no)
EP (1) EP0532915B1 (no)
JP (1) JP3361126B2 (no)
KR (2) KR100264623B1 (no)
AT (1) ATE147407T1 (no)
AU (1) AU656396B2 (no)
CA (1) CA2076424C (no)
CZ (1) CZ290341B6 (no)
DE (1) DE59207835D1 (no)
DK (1) DK0532915T3 (no)
ES (1) ES2096686T3 (no)
FI (1) FI102842B (no)
GR (1) GR3022895T3 (no)
HR (1) HRP940834B1 (no)
HU (1) HU210431B (no)
IL (1) IL102859A (no)
NO (1) NO303452B1 (no)
SG (1) SG46639A1 (no)
SK (1) SK281333B6 (no)
TW (1) TW224104B (no)
YU (1) YU66892A (no)
ZA (1) ZA926232B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE184611T1 (de) * 1991-11-29 1999-10-15 Hoechst Ag Peptide mit insulinartiger wirkung
ES2159283T3 (es) * 1992-02-29 2001-10-01 Aventis Res & Tech Gmbh & Co Complejos que contienen glicosil-fosfatidilinositol-proteinas y derivados de acido colanico, procedimiento para su preparacion y su utilizacion.
US5652221A (en) * 1994-11-07 1997-07-29 The University Of Virginia Patent Foundation Method of treating defective glucose metabolism using synthetic insulin substances
GB9618929D0 (en) 1996-09-11 1996-10-23 Univ London Metal containing carbohydrates from human tissue which regulate glycogen metabolism
GB9618934D0 (en) * 1996-09-11 1996-10-23 Univ London Inositol phosphoglycans for therapeutic use in the treatment of diabetes and obesity
GB9618930D0 (en) 1996-09-11 1996-10-23 Univ London Metal containing carbohydrates from human tissue which regulate lipogenic activity
DE19649350A1 (de) * 1996-11-28 1998-06-04 Hoechst Ag Inositolglykane mit insulinartiger Wirkung
KR100481746B1 (ko) * 1996-11-28 2005-08-10 훽스트 악티엔게젤샤프트 인슐린-유사작용을갖는이노시톨글리칸및이를포함하는약제학적제제
EP2158923B1 (en) 1998-08-06 2013-02-27 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
CH697081A5 (de) * 2002-01-22 2008-04-30 Andreas F Dr Schaub Zusammensetzung für die Unterstützung der Geburt eines menschlichen Föten.
EP1378517A1 (en) * 2002-07-05 2004-01-07 Aventis Pharma Deutschland GmbH Phosphoinositolglycan (PIG) binding protein from adipocytes
CA2491555C (en) * 2002-07-10 2012-09-11 Massachusetts Institute Of Technology Solid-phase and solution-phase synthesis of glycosylphosphatidylinositol glycans
ITMI20030237A1 (it) * 2003-02-11 2004-08-12 Indena Spa Uso della conglutina di lupino per il trattamento del
DE102004054552A1 (de) * 2004-11-11 2006-05-18 Hcb Happy Child Birth Holding Ag Neue Zusammensetzung zur Erleichterung der Humangeburt
RU2435847C2 (ru) 2005-04-11 2011-12-10 Савиент Фармасьютикалз, Инк. Вариантная форма урат-оксидазы и ее использование
PL3321359T3 (pl) 2005-04-11 2021-06-28 Horizon Pharma Rheumatology Llc Wariantowe postacie oksydazy moczanowej i ich zastosowanie
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
KR101861547B1 (ko) 2009-06-25 2018-07-02 크레알타 파마슈티칼스 엘엘씨 페길화된 유리카아제 치료 중에 혈청 요산을 모니터링하여 주입 반응의 위험성 및 반응의 항체­매개 상실을 예측하는 방법 및 키트
CN102270762B (zh) * 2010-06-03 2014-08-20 清华大学 锂离子电池电极浆料及应用该电极浆料制备的电极片

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
US4906468A (en) * 1986-04-11 1990-03-06 The Rockefeller University Insulin activity messengers, their antibodies, and thereof
US4839466A (en) * 1986-04-11 1989-06-13 The Rockefeller University Insulin activity messengers

Also Published As

Publication number Publication date
ATE147407T1 (de) 1997-01-15
SG46639A1 (en) 1998-02-20
AU656396B2 (en) 1995-02-02
AU2110992A (en) 1993-02-25
DE59207835D1 (de) 1997-02-20
FI923702A (fi) 1993-02-21
EP0532915B1 (de) 1997-01-08
JP3361126B2 (ja) 2003-01-07
HRP940834B1 (en) 2000-08-31
CA2076424A1 (en) 1993-02-21
GR3022895T3 (en) 1997-06-30
NO303452B1 (no) 1998-07-13
JPH05301891A (ja) 1993-11-16
EP0532915A2 (de) 1993-03-24
FI923702A0 (fi) 1992-08-18
YU66892A (sh) 1995-10-24
IL102859A0 (en) 1993-01-31
HUT62013A (en) 1993-03-29
DK0532915T3 (da) 1997-07-07
TW224104B (no) 1994-05-21
ZA926232B (en) 1993-04-28
CZ255392A3 (en) 1993-03-17
CZ290341B6 (cs) 2002-07-17
KR100318706B1 (ko) 2001-12-28
ES2096686T3 (es) 1997-03-16
HRP940834A2 (en) 1997-04-30
EP0532915A3 (en) 1994-05-18
IL102859A (en) 1998-12-27
SK255392A3 (en) 1995-02-08
FI102842B1 (fi) 1999-02-26
NO923252D0 (no) 1992-08-19
FI102842B (fi) 1999-02-26
KR930004327A (ko) 1993-03-22
SK281333B6 (sk) 2001-02-12
CA2076424C (en) 2003-06-03
US5624903A (en) 1997-04-29
KR100264623B1 (ko) 2000-09-01
HU210431B (en) 1995-04-28

Similar Documents

Publication Publication Date Title
NO923252L (no) Fosfoinositolglykan-peptid med insulinlignende virkning
HUT64235A (en) Process for the production of medical prepartives containing by means of peroral introduction of insuline
EP0339237A3 (en) Phenol substituted gem-diphosphonate derivatives, process for their preparation and pharmaceutical compositions containing them
HU9301794D0 (en) Medical preparative for treating chronical viral diseases of liver as well qs method for preparing said medicament
GR3025488T3 (en) Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions
PT87523A (pt) Mischkristalle aus insulin und insulinderivaten verfahren zur herstellung dieser mischkristalle diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
FI953525A0 (fi) Kemiskt syntetiseringsfoerfarande foer framstaellning av ett protein eller en polypeptid
FI892185A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten peptidiyhdisteiden valmistamiseksi
EP0339549A3 (en) Tyr-peptide analogs
AU611113B2 (en) Basically substituted phenylacetonitriles, their preparation and drugs containing these compounds
EP0193910A3 (en) Synthesis of a derivative of grf and intermediate peptides
ATE86260T1 (de) Peptid-molekuele, wirksam gegen gram-positive keime.
ES2147519B1 (es) Utilizacion de un compuesto de tipo retinoide para modular in vivo la actividad desacopladora de la proteina ucp2.
EP0491361A3 (en) Short peptides having the effect of insulin
MX9206732A (es) Nuevas proteinas inhibidoras de trombina a partir de sanguijuelas de tierra.
MY103751A (en) Heterobicycloalkanes having pesticidal activity
AU542310B2 (en) Glicentin related purified peptide having 30 amino acids
AU5110390A (en) Cdna coding for placental protein 9 (pp9), the isolation and use thereof
AU1568995A (en) Analogs of thymosin alpha1

Legal Events

Date Code Title Description
MK1K Patent expired